Abstract
Priyata Kalra, Bastian Kister, Rebekka Fendt, Mario Köster, Julia Pulverer, Sven Sahle, Lars Kuepfer, Ursula Kummer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
ADME/PK as part of a rational approach to drug discovery
10.1016/s1359-6446(00)01540-3 · 2000
Pharmacokinetic/pharmacodynamic studies in drug product development
10.1002/jps.1167 · 2002
Applied concepts in PBPK modeling: how to build a PBPK/PD model
10.1002/psp4.12134 · 2016
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
10.1007/s10928-017-9559-4 · 2018
Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework
10.1038/nrd4309 · 2014
Systems pharmacology - Towards the modeling of network interactions
10.1016/j.ejps.2016.04.027 · 2016
Functional comparison of interferon-α subtypes reveals potent Hepatitis B virus suppression by a concerted action of interferon-α and interferon-γ signaling
10.1002/hep.31282 · 2021
Transcriptomics in interferon-α-treated patients identifies inflammation-, neuroplasticity- and oxidative stress-related signatures as predictors and correlates of depression
10.1038/npp.2016.50 · 2016
Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach
10.1371/journal.pone.0209587 · 2019
Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon α-induced early antiviral signalling
10.1111/j.1742-4658.2010.07880.x · 2010
Temporal and spatial resolution of type I and III interferon responses in vivo
10.1128/jvi.00303-10 · 2010
Expansion of functional personalized cells with specific transgene combinations
10.1038/s41467-018-03408-4 · 2018
Preparation of isolated rat liver cells
10.1016/s0091-679x(08)61797-5 · 1976
COPASI--a complex pathway simulator
10.1093/bioinformatics/btl485 · 2006
Mathematical modeling of intracellular signaling pathways
10.1186/1471-2202-7-s1-s10 · 2006
10.1007/b97636
10.1007/b97636 · 2004
Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice
10.1089/jir.1986.6.207 · 1986
The kinetics of interferon clearance in mice: comparison of mouse and human interferon
1984
Study of the in vivo priming effect of interferon in mice
10.1099/0022-1317-67-12-2731 · 1986
Antiviral actions of interferons
10.1128/cmr.14.4.778-809.2001 · 2001
Mx proteins: antiviral gatekeepers that restrain the uninvited
10.1128/mmbr.00024-13 · 2013
Interferon-inducible antiviral effectors
10.1038/nri2314 · 2008
Mouse Mx2 gene: organization, mRNA expression and the role of the interferon-response promoter in its regulation
10.1016/s0378-1119(03)00428-1 · 2003
Ensemble modeling for analysis of cell signaling dynamics
10.1038/nbt1330 · 2007
Development of a physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats
10.3389/fphys.2012.00494 · 2013
Extrapolating from animals to humans
2012
Issues in collecting, processing and storing human tissues and associated information to support biomedical research
10.3233/cbm-2011-0183 · 2010
Genomic responses in mouse models poorly mimic human inflammatory diseases
10.1073/pnas.1222878110 · 2013
Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation
10.1111/imr.12001 · 2012
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice
10.1124/jpet.110.167650 · 2010
Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor
1996
Of mice and not men: differences between mouse and human immunology
10.4049/jimmunol.172.5.2731 · 2004
Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway
10.1002/eji.202048793 · 2021
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
10.1053/j.gastro.2005.01.059 · 2005
Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs
10.1046/j.1365-2516.2000.00444.x · 2000
Identifying responders and nonresponders to interferon therapy in multiple sclerosis
2014
Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?
2002
Type I interferons in infectious disease
10.1038/nri3787 · 2015
Interferons α and β in cancer: therapeutic opportunities from new insights
10.1038/s41573-018-0011-2 · 2019
Cytokines in clinical cancer immunotherapy
10.1038/s41416-018-0328-y · 2019
Quantitative systems pharmacology approaches for immuno-oncology: adding virtual patients to the development paradigm
10.1002/cpt.1987 · doi-reference